The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal...
H.C. Wainwright launched coverage of Acasti Pharma (NASDAQ:ACST) and Matinas BioPharma (NYSE American:MTNB) with “buy” ratings and price targets of $6 and $4, respectively.
Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...